H.C. Wainwright says the departure of Center for Biologics Evaluation and Research Director Vinay Prasad at the end of April “reshapes the regulatory calculus” for uniQure’s (QURE) AMT-130. H.C. Wainwright has “continued conviction” in AMT-130’s existing dataset and uniQure’s broader pipeline. As such, it thinks the shares are “poised for a value inflection.” H.C. Wainwright reiterates a Buy rating on uniQure with a $70 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure price target raised to $31 from $16 at Chardan
- U.S. Chess Champion Sitting on Huge 42.33% uniQure (QURE) Loss
- Midday Fly By: Hims & Hers reaches Novo deal, Live Nation settles with DOJ
- Wells gives uniQure second upgrade on Prasad FDA departure
- uniQure upgraded to Overweight from Equal Weight at Wells Fargo